These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32267476)

  • 21. The immunological disease continuum of inflammation against self as an explanation for the lack of association between hidradenitis suppurativa and autoimmune thyroid disease.
    De Vita V; McGonagle D
    Clin Exp Dermatol; 2018 Jul; 43(5):601-603. PubMed ID: 29327479
    [No Abstract]   [Full Text] [Related]  

  • 22. Pain management in hidradenitis suppurativa and a proposed treatment algorithm.
    Savage KT; Singh V; Patel ZS; Yannuzzi CA; McKenzie-Brown AM; Lowes MA; Orenstein LAV
    J Am Acad Dermatol; 2021 Jul; 85(1):187-199. PubMed ID: 32950543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Central sensitisation and chronic organ-related pain].
    Lidbeck J
    Lakartidningen; 2016 Oct; 113():. PubMed ID: 27779724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of Routine Diabetes Screening for Patients with Hidradenitis Suppurativa.
    Ahmad S; Riddle AO; Sayed CJ
    J Invest Dermatol; 2021 Apr; 141(4):927-930. PubMed ID: 32910937
    [No Abstract]   [Full Text] [Related]  

  • 25. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?
    Johnston DGW; Kirby B; Tobin DJ
    Exp Dermatol; 2021 Oct; 30(10):1554-1568. PubMed ID: 34418166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.
    Jenei A; Dajnoki Z; Medgyesi B; Gáspár K; Béke G; Kinyó Á; Méhes G; Hendrik Z; Dinya T; Törőcsik D; Zouboulis CC; Prens EP; Bíró T; Szegedi A; Kapitány A
    J Invest Dermatol; 2019 Apr; 139(4):964-968. PubMed ID: 30391261
    [No Abstract]   [Full Text] [Related]  

  • 27. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2.
    Vekic DA; Cains GD
    Australas J Dermatol; 2018 Nov; 59(4):261-266. PubMed ID: 29363099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated parathyroid hormone-related protein and hypercalcemia in a patient with cutaneous squamous cell carcinoma complicating hidradenitis suppurativa.
    Welsh DA; Powers JS
    South Med J; 1993 Dec; 86(12):1403-4. PubMed ID: 8272921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nutritional neurobiology and central nervous system sensitisation: missing link in a comprehensive treatment for chronic pain?
    Nijs J; Elma Ö; Yilmaz ST; Mullie P; Vanderweeën L; Clarys P; Deliens T; Coppieters I; Weltens N; Van Oudenhove L; Malfliet A
    Br J Anaesth; 2019 Nov; 123(5):539-543. PubMed ID: 31492528
    [No Abstract]   [Full Text] [Related]  

  • 30. General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression.
    Boyer N; Dallel R; Artola A; Monconduit L
    Pain; 2014 Jul; 155(7):1196-1205. PubMed ID: 24631586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central sensitization in chronic low back pain: A narrative review.
    Sanzarello I; Merlini L; Rosa MA; Perrone M; Frugiuele J; Borghi R; Faldini C
    J Back Musculoskelet Rehabil; 2016 Nov; 29(4):625-633. PubMed ID: 27062464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complications of hidradenitis suppurativa.
    Yuan JT; Naik HB
    Semin Cutan Med Surg; 2017 Jun; 36(2):79-85. PubMed ID: 28538749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central sensitization and changes in conditioned pain modulation in people with chronic nonspecific low back pain: a case-control study.
    Corrêa JB; Costa LO; de Oliveira NT; Sluka KA; Liebano RE
    Exp Brain Res; 2015 Aug; 233(8):2391-9. PubMed ID: 25963754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What to call the amplification of nociceptive signals in the central nervous system that contribute to widespread pain?
    Woolf CJ
    Pain; 2014 Oct; 155(10):1911-1912. PubMed ID: 25083929
    [No Abstract]   [Full Text] [Related]  

  • 35. Translational aspects of central sensitization induced by primary afferent activity: what it is and what it is not.
    Hansson P
    Pain; 2014 Oct; 155(10):1932-1934. PubMed ID: 25067835
    [No Abstract]   [Full Text] [Related]  

  • 36. [Squamous cell carcinoma as a rare complication of hidradenitis suppurativa].
    Vogelaar FJ; Willems JM
    Ned Tijdschr Geneeskd; 2010; 154():A1137. PubMed ID: 20456772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hidradenitis suppurativa and associated diseases.
    Pescitelli L; Ricceri F; Prignano F
    G Ital Dermatol Venereol; 2018 Jun; 153(3 Suppl 2):8-17. PubMed ID: 30468375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propagation of spinal nociceptive activity in the spatial and temporal domains.
    Jongen JL; Holstege JC
    Neuroscientist; 2012 Feb; 18(1):8-14. PubMed ID: 21362687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronification of Pain: Mechanisms, Current Understanding, and Clinical Implications.
    Pak DJ; Yong RJ; Kaye AD; Urman RD
    Curr Pain Headache Rep; 2018 Feb; 22(2):9. PubMed ID: 29404791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa.
    Mozeika E; Pilmane M; Nürnberg BM; Jemec GB
    Acta Derm Venereol; 2013 May; 93(3):301-4. PubMed ID: 23096596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.